HC Wainwright Weighs in on Oculis’ Q1 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS) – Equities research analysts at HC Wainwright cut their Q1 2026 earnings estimates for Oculis in a research report issued to clients and investors on Wednesday, March 4th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.47) per share for the quarter, down from their previous forecast of ($0.46). HC Wainwright has a “Buy” rating and a $44.00 price target on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.50) EPS and FY2026 earnings at ($1.95) EPS.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.14 million. Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%.

OCS has been the subject of several other research reports. Stifel Nicolaus upped their price objective on Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday. Wall Street Zen upgraded shares of Oculis from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Bank of America dropped their target price on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Thursday, January 22nd. Finally, Chardan Capital reiterated a “buy” rating and set a $51.00 price objective on shares of Oculis in a research report on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $43.50.

Oculis Price Performance

Shares of NASDAQ:OCS opened at $27.74 on Friday. The stock’s 50 day moving average price is $26.03 and its 200 day moving average price is $21.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.96 and a quick ratio of 4.47. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -12.22 and a beta of 0.29. Oculis has a 12 month low of $14.00 and a 12 month high of $30.68.

Institutional Trading of Oculis

A number of hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its holdings in shares of Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after buying an additional 6,384 shares in the last quarter. Marshall Wace LLP purchased a new position in Oculis during the 2nd quarter valued at about $393,000. Bosun Asset Management LLC acquired a new position in shares of Oculis in the 2nd quarter valued at about $378,000. Bank of America Corp DE lifted its position in shares of Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares in the last quarter. Finally, Woodline Partners LP boosted its holdings in shares of Oculis by 65.8% during the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after purchasing an additional 33,265 shares during the period. Hedge funds and other institutional investors own 22.30% of the company’s stock.

More Oculis News

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Privosegtor received Breakthrough Therapy designation for optic neuritis and Oculis is advancing registrational programs in optic neuropathies — a large addressable U.S. market (>$7B) if trials succeed. This is a material clinical/regulatory positive for OCS. Article Title
• Positive Sentiment: Topline readout for OCS-01 in diabetic macular edema (DIAMOND Phase 3) is on track for Q2 2026 — a near-term binary catalyst that could materially re‑rate the stock if positive. Article Title
• Positive Sentiment: Wall Street support increased: Needham and HC Wainwright raised price targets (to $40 and $44 respectively) and maintain buy ratings — these upgrades can attract investor interest and support higher valuations. Article Title
• Positive Sentiment: Significant institutional accumulation reported (multiple funds added large positions in Q4 2025), which can provide demand support into upcoming catalysts. Article Title
• Neutral Sentiment: Oculis is presenting at multiple investor conferences in March (Leerink Global Healthcare Conference, LifeSci Capital Biotech Forum) — increases management visibility and provides opportunities for Q&A but no direct clinical data. Article Title
• Neutral Sentiment: Company filed audited 2025 consolidated financial statements and MD&A with the SEC — increases transparency; separately, Oculis renewed a $100M ATM program (capital flexibility that can fund development but may dilute if used). Article Title
• Negative Sentiment: Quarterly results missed EPS estimates (reported ($0.51) vs. consensus ($0.43)); while revenue beat estimates, margins and ROE remain deeply negative — a reminder of biotech execution and cash‑burn risk until pivotal approvals. Article Title
• Negative Sentiment: Notifications show RSU vesting/settlement for a director — standard governance activity but adds modest share count pressure/short‑term dilution. Article Title

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.